Accord BioPharma’s HERCESSI™ Receives Significant Formulary Status Expansion Accord BioPharma's oncology treatment HERCESSI™ has been added to Express Scripts' preferred formulary list, enhancing patient access to affordable cancer therapies.

Accord BioPharma’s HERCESSI™ Receives Significant Formulary Status Expansion #United_States #Raleigh #Accord_BioPharma #HERCESSI #HERCEPTIN

Accord BioPharma's IMULDOSA® Receives Preferred Status in National Formularies Accord BioPharma's IMULDOSA® has been added to Express Scripts' national formularies, enhancing patient access to this vital therapy for chronic conditions.

Accord BioPharma's IMULDOSA® Receives Preferred Status in National Formularies #United_States #Raleigh #Accord_BioPharma #Ustekinumab #IMULDOSA®

Accord BioPharma Receives FDA Approval for New Denosumab Biosimilars Accord BioPharma has announced the FDA approval of two denosumab biosimilars, OSVYRTI and JUBEREQ, expanding its offerings in treatments for osteoporosis and cancer-related conditions.

Accord BioPharma Receives FDA Approval for New Denosumab Biosimilars #United_States #Accord_BioPharma #Raleigh,_N.C. #Denosumab #OSVYRTI

Accord BioPharma Launches IMULDOSA® at Unmatched Price for Patients Needing Treatment Accord BioPharma introduces IMULDOSA®, a biosimilar to STELARA®, with a significant price reduction to enhance accessibility for patients in need.

Accord BioPharma Launches IMULDOSA® at Unmatched Price for Patients Needing Treatment #United_States #Raleigh #Accord_BioPharma #Imuldosa #Ustekinumab

Intas Pharmaceuticals and Accord BioPharma Become Leading Providers of Pegfilgrastim Through UDENYCA Acquisition Intas Pharmaceuticals, along with Accord BioPharma, solidifies its position as a top global provider of Pegfilgrastim after acquiring UDENYCA from Coherus BioSciences.

Intas Pharmaceuticals and Accord BioPharma Become Leading Providers of Pegfilgrastim Through UDENYCA Acquisition #India #Accord_BioPharma #UDENYCA #Intas_Pharmaceuticals #Ahmedabad

Intas Pharmaceuticals and Accord BioPharma's Strategic Move to Dominate Pegfilgrastim Market through UDENYCA Acquisition Intas Pharmaceuticals and Accord BioPharma have strengthened their market position as major providers of pegfilgrastim globally with the acquisition of UDENYCA, enhancing strategic growth.

Intas Pharmaceuticals and Accord BioPharma's Strategic Move to Dominate Pegfilgrastim Market through UDENYCA Acquisition #India #Accord_BioPharma #UDENYCA #Intas_Pharmaceuticals #Ahmedabad

Intas Pharmaceuticals and Accord BioPharma Rise to Top Global Pegfilgrastim Suppliers with UDENYCA Acquisition Intas Pharmaceuticals strengthens its global presence in pegfilgrastim supply through the strategic acquisition of UDENYCA from Coherus BioSciences.

Intas Pharmaceuticals and Accord BioPharma Rise to Top Global Pegfilgrastim Suppliers with UDENYCA Acquisition #USA #Accord_BioPharma #UDENYCA #Intas_Pharmaceuticals #Ahmedabad

Intas Pharmaceuticals and Accord BioPharma Strengthen Global Pegfilgrastim Market with UDENYCA Acquisition Intas Pharmaceuticals, in collaboration with Accord BioPharma, has acquired UDENYCA, establishing itself as a major pegfilgrastim supplier worldwide.

Intas Pharmaceuticals and Accord BioPharma Strengthen Global Pegfilgrastim Market with UDENYCA Acquisition #India #Accord_BioPharma #UDENYCA #Ahmedabad #Pegfilgrastim

Accord BioPharma Expands Its U.S. Biosimilar Portfolio with UDENYCA Acquisition Accord BioPharma has finalized its acquisition of UDENYCA, enhancing its biosimilar offerings. This move signifies a strong commitment to patient care and industry growth.

Accord BioPharma Expands Its U.S. Biosimilar Portfolio with UDENYCA Acquisition #United_States #Raleigh #Accord_BioPharma #UDENYCA #Coherus_BioSciences

Accord BioPharma Enhances Biosimilar Portfolio with New BAT2506 Agreement Accord BioPharma has signed a pivotal licensing deal with Bio-Thera for BAT2506, a proposed Golimumab biosimilar, expanding its capabilities in immunology.

Accord BioPharma Enhances Biosimilar Portfolio with New BAT2506 Agreement #USA #Raleigh #Accord_BioPharma #Bio-Thera #BAT2506

Accord BioPharma Celebrates 10,000 Patients Treated with CAMCEVI® for Advanced Prostate Cancer Accord BioPharma announces a significant milestone with over 10,000 patients receiving CAMCEVI®, a leading treatment for advanced prostate cancer. This reflects their commitment to accessible care.

Accord BioPharma Celebrates 10,000 Patients Treated with CAMCEVI® for Advanced Prostate Cancer #United_States #Raleigh #Accord_BioPharma #CAMCEVI #Prostate_Cancer

Accord BioPharma and Intas Pharmaceuticals Aim for Growth with UDENYCA® Acquisition Accord BioPharma and Intas Pharmaceuticals are set to enhance their market position by acquiring the UDENYCA® business from Coherus BioSciences, promising growth and patient-centric solutions.

Accord BioPharma and Intas Pharmaceuticals Aim for Growth with UDENYCA® Acquisition #United_States #Raleigh #Accord_BioPharma #UDENYCA #Intas_Pharmaceuticals